Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dexanabinol Pharmos.

E Pop1

  • 1Alchem Laboratories Corporation, Alachua, FL 32615, USA. emilpop@aol.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
PubMed
Summary

Dexanabinol, a non-psychotropic NMDA receptor antagonist, shows promise for treating neurological conditions like traumatic brain injury and multiple sclerosis. It exhibits potent antioxidant and anti-inflammatory effects, with ongoing research into novel formulations and prodrugs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The Oradea study regarding the epidemiology factors in ischemic cardiopathy].

Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi·2014
Same author

The role of external defects in chemical sensing of graphene field-effect transistors.

Nano letters·2013
Same author

Long hydrocarbon chain diols and diacids with central ether or ketone moieties that favorably alter lipid disorders.

Die Pharmazie·2006
Same author

Trends in neuroprotection.

Archivos de la Sociedad Espanola de Oftalmologia·2002
Same author

Attempts of ranking in a series of synthetic nonpsychotropic cannabinoids.

SAR and QSAR in environmental research·2001
Same author

Nonpsychotropic synthetic cannabinoids.

Current pharmaceutical design·2000

Area of Science:

  • Neuropharmacology
  • Drug Development

Background:

  • Dexanabinol is a non-psychotropic NMDA receptor antagonist.
  • It is being developed by Pharmos Corp for various neurological and cardiovascular conditions.
  • Unlike its enantiomer HU-210, it does not interact with cannabinoid receptors.

Purpose of the Study:

  • To evaluate the potential of dexanabinol in treating cerebral ischemia, glaucoma, Alzheimer's disease, cardiac failure, head injury, and multiple sclerosis (MS).
  • To develop new prodrugs and novel formulations of dexanabinol.
  • To explore dexanabinol compounds for various indications.

Main Methods:

  • Phase III trials for traumatic brain injury (TBI).
  • Development of prodrugs and novel formulations supported by NIH grant.
  • Patent applications covering uses in MS, pain, and neuroprotection.

Main Results:

  • Dexanabinol demonstrated more effective antioxidant and anti-inflammatory properties than MK-801.
  • It is generally well tolerated and appears toxicologically safe.
  • A patent was allowed for its use in treating MS.

Conclusions:

  • Dexanabinol is a promising therapeutic agent for neurological disorders.
  • Ongoing research focuses on optimizing its delivery and efficacy through prodrugs and new formulations.
  • The potential market for dexanabinol in treating severe head trauma is estimated at $1 billion annually.

Related Experiment Videos